Exosome Exotherapy: Lior Shaltiel on a Platform for CNS Regeneration
Today, we sit down with Dr. Lior Shaltiel of NurExone Biologics to explore how exosome-based delivery of siRNA could...
Anteris Gets First EU Clearance for DuraVR Pivotal Trial
The PARADIGM pivotal trial will randomize approximately 1,000 “all-comer” patients with severe calcific aortic stenosis 1:1 to the DurAVR...
Artelo to Present Expanded Clinical Data at Cannabinoid Summit
Patients in Artelo’s CAReS Phase 2 trial of ART27.13, a once-daily dual cannabinoid agonist for cancer-related anorexia, gained an...
MMI’s New Robotic Study Enrolls Its First Patient in U.S.
Up to 455 patients across two cohorts will be enrolled in a prospective, multi-center U.S. study evaluating the Symani...
Aprea Sets Phase 2 Dose for ATRN-119 Combination Therapy
Aprea set the monotherapy recommended Phase 2 dose for ATRN-119, its oral ATR inhibitor, at 1,100 mg once daily...
First Patient Enrolled for Prostate Cancer Trial in Japan
Curium’s global Phase 3 ECLIPSE trial of 177Lu-PSMA-I&T met its primary endpoint with statistically significant, clinically meaningful benefit in...
Eyepoint Begins Pivotal Phase 3 Trial for Duravyu™ in DME
Phase 2 signals for EyePoint’s vorolanib intravitreal insert include an approximately 88% reduction in treatment burden at six months...
Surging Lung Cancer ADC Market: FDA Trials & Opportunity
Global lung cancer ADCs have moved from niche to scale: the new Kuick Research analysis pegs 2024 revenue at...
OX40 Targeted Therapy Trials & Market Opportunity Insight 2026
Across OX40/OX40L programs, concrete signals are emerging: in asthma, an amlitelimab-responsive subgroup reported more than a 70% reduction in...
Promising Pancreatic Cancer Data from Cellectar Biosciences
In three pancreatic ductal adenocarcinoma xenograft models (PANC-1, MIA PaCa-2, and BxPC-3), Cellectar’s actinium-225 phospholipid ether conjugate CLR 225...